Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Soluble CD163 predicts outcome in both chemoimmunotherapy and targeted therapy–treated mantle cell lymphoma

Nikkarinen, Anna ; Lokhande, Lavanya LU ; Amini, Rose Marie ; Jerkeman, Mats LU ; Porwit, Anna LU ; Molin, Daniel ; Enblad, Gunilla ; Kolstad, Arne ; Räty, Riikka and Hutchings, Martin , et al. (2023) In Blood Advances 7(18). p.5304-5313
Abstract

The outcome for patients with mantle cell lymphoma (MCL) has drastically improved with new treatments directed toward the tumor immune microenvironment, where macrophages play an important role. In MCL, the presence of M2 macrophages defined by CD163 expression in diagnostic biopsies has been associated with a worse prognosis. An alternative way to assess the abundance of M2 macrophages is by measuring the level of soluble CD163 in serum (sCD163). We aimed to investigate the prognostic value of sCD163 in 131 patients with MCL. We found that high sCD163 at diagnosis was associated with shorter progression-free survival (PFS) and shorter overall survival (OS) in 81 patients who were newly diagnosed and subsequently treated with... (More)

The outcome for patients with mantle cell lymphoma (MCL) has drastically improved with new treatments directed toward the tumor immune microenvironment, where macrophages play an important role. In MCL, the presence of M2 macrophages defined by CD163 expression in diagnostic biopsies has been associated with a worse prognosis. An alternative way to assess the abundance of M2 macrophages is by measuring the level of soluble CD163 in serum (sCD163). We aimed to investigate the prognostic value of sCD163 in 131 patients with MCL. We found that high sCD163 at diagnosis was associated with shorter progression-free survival (PFS) and shorter overall survival (OS) in 81 patients who were newly diagnosed and subsequently treated with chemoimmunotherapy. The same was seen in a cohort of 50 patients with relapsed MCL that were mainly treated within the phase 2 Philemon-trial with rituximab, ibrutinib, and lenalidomide. In patients who were newly diagnosed and had low levels of sCD163, 5-year survival was 97%. There was a moderate correlation between sCD163 and tissue CD163. The association with a poor prognosis was independent of MCL international prognostic index, Ki67, p53 status, and blastoid morphology, as assessed in a multivariable Cox proportional hazards model. In this study, high sCD163 was associated with both shorter PFS and shorter OS, showing that high levels of the M2 macrophage marker sCD163 is an independent negative prognostic factor in MCL, both in the chemoimmunotherapy and ibrutinib/lenalidomide era. In addition, low sCD163 levels identify patients with MCL with a very good prognosis.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; ; ; and , et al. (More)
; ; ; ; ; ; ; ; ; ; ; ; and (Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Blood Advances
volume
7
issue
18
pages
10 pages
publisher
American Society of Hematology
external identifiers
  • scopus:85173511372
  • pmid:37389827
ISSN
2473-9529
DOI
10.1182/bloodadvances.2023010052
language
English
LU publication?
yes
id
e2bbd5f9-8895-4126-b34f-c2b22829d6fb
date added to LUP
2023-12-12 08:52:12
date last changed
2024-12-20 03:50:02
@article{e2bbd5f9-8895-4126-b34f-c2b22829d6fb,
  abstract     = {{<p>The outcome for patients with mantle cell lymphoma (MCL) has drastically improved with new treatments directed toward the tumor immune microenvironment, where macrophages play an important role. In MCL, the presence of M2 macrophages defined by CD163 expression in diagnostic biopsies has been associated with a worse prognosis. An alternative way to assess the abundance of M2 macrophages is by measuring the level of soluble CD163 in serum (sCD163). We aimed to investigate the prognostic value of sCD163 in 131 patients with MCL. We found that high sCD163 at diagnosis was associated with shorter progression-free survival (PFS) and shorter overall survival (OS) in 81 patients who were newly diagnosed and subsequently treated with chemoimmunotherapy. The same was seen in a cohort of 50 patients with relapsed MCL that were mainly treated within the phase 2 Philemon-trial with rituximab, ibrutinib, and lenalidomide. In patients who were newly diagnosed and had low levels of sCD163, 5-year survival was 97%. There was a moderate correlation between sCD163 and tissue CD163. The association with a poor prognosis was independent of MCL international prognostic index, Ki67, p53 status, and blastoid morphology, as assessed in a multivariable Cox proportional hazards model. In this study, high sCD163 was associated with both shorter PFS and shorter OS, showing that high levels of the M2 macrophage marker sCD163 is an independent negative prognostic factor in MCL, both in the chemoimmunotherapy and ibrutinib/lenalidomide era. In addition, low sCD163 levels identify patients with MCL with a very good prognosis.</p>}},
  author       = {{Nikkarinen, Anna and Lokhande, Lavanya and Amini, Rose Marie and Jerkeman, Mats and Porwit, Anna and Molin, Daniel and Enblad, Gunilla and Kolstad, Arne and Räty, Riikka and Hutchings, Martin and Weibull, Caroline E. and Hollander, Peter and Ek, Sara and Glimelius, Ingrid}},
  issn         = {{2473-9529}},
  language     = {{eng}},
  month        = {{09}},
  number       = {{18}},
  pages        = {{5304--5313}},
  publisher    = {{American Society of Hematology}},
  series       = {{Blood Advances}},
  title        = {{Soluble CD163 predicts outcome in both chemoimmunotherapy and targeted therapy–treated mantle cell lymphoma}},
  url          = {{http://dx.doi.org/10.1182/bloodadvances.2023010052}},
  doi          = {{10.1182/bloodadvances.2023010052}},
  volume       = {{7}},
  year         = {{2023}},
}